Why the study?
Does tumor whole-genome sequencing improve VTE prediction compared to clinical risk scores alone in patients with metastasized solid cancer?
Population
Patients with metastasized solid cancer
Comparison
Tumor whole-genome sequencing vs Clinical risk scores alone
Design
Cohort
Authors
Loading...
Tumor whole-genome sequencing shows potential to enhance clinical risk scores for predicting venous thromboembolism in patients with metastasized solid cancer.
Does tumor whole-genome sequencing improve VTE prediction compared to clinical risk scores alone in patients with metastasized solid cancer?
Tumor whole-genome sequencing shows potential to enhance clinical risk scores for predicting venous thromboembolism in patients with metastasized solid cancer.
Mulder et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: